Training activity information
Details
Interpret results of cfDNA assay and suggest further actions for treatment/therapy
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Principles and purpose of technique
- Limitations and sample considerations
- Appropriateness of testing in line with current guidelines
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What clinical information does cfDNA analysis provide in the context of advanced therapies and stem cells?
- What are the principles behind cfDNA assays used in your department? What are the typical results and how are they reported?
- What are the clinical implications of different cfDNA findings in the context of treatment and therapy monitoring? What are the relevant clinical guidelines or protocols for acting on these results?
- Will you review the principles and applications of cfDNA assays?
- Will you study examples of cfDNA reports and their clinical interpretation?
- Will you discuss potential scenarios with your training officer or a clinical scientist?
- What challenges might you face in interpreting complex or ambiguous results?
- How confident do you feel in making suggestions for patient management based on laboratory data?
In action
- As you look at the cfDNA results, how are you systematically analysing the different parameters and considering their clinical significance?
- When formulating potential further actions, what factors (e.g., the specific genetic alterations, patient history) are influencing your decisions?
- Are you finding it easier to interpret certain types of cfDNA results compared to others? What makes the difference?
- What challenges are you facing (e.g., complex genomic information, limited clinical context)? How are you trying to make sense of the data?
- What are you learning about the clinical application of cfDNA assays and their role in treatment decisions as you interpret the results?
- If you are uncertain about the interpretation or the most appropriate next steps, are you considering alternative possibilities and when you might need to consult with a senior colleague?
On action
- Summarise the key findings of the cfDNA assay results you interpreted.
- What specific genetic alterations or biomarkers were identified and what were their levels or significance?
- What did you learn about the clinical relevance of the specific cfDNA findings in the context of potential treatment or therapy?
- What resources did you use to aid your interpretation (e.g., databases, literature)?
- Were there any unexpected results or patterns in the data?
- What challenges did you encounter in interpreting the findings and suggesting further actions?
- Reflecting on your analysis, how did your immediate consideration of the patient’s clinical context and potential treatment options guide your interpretation?
- How important is the accurate interpretation of cfDNA assay results for guiding personalised treatment strategies and monitoring disease progression in haematological disorders?
- What specific genetic alterations or their clinical implications do you want to learn more about in the context of cfDNA analysis?
- How will this experience influence your approach to interpreting complex genomic data and integrating it with clinical information?
- What are your next steps in terms of discussing your interpretation and proposed actions with your supervisor or reviewing relevant clinical guidelines?
- Do you need any further resources or training on the principles of cfDNA analysis or its application in haematology?
Beyond action
- Have you interpreted other cfDNA assay results since this training activity, perhaps in different clinical contexts related to haematological conditions? How did your interpretation compare?
- Have you reviewed your initial reflections (reflect-on-action) for this activity in light of subsequent cases or new developments in cfDNA testing?
- Consider other training activities or experiences where you have had to integrate laboratory results with clinical information to guide patient management. How did your approach compare?
- Has this DTA improved your understanding of the application of novel and evolving therapies in the treatment of haematological conditions?
- Do you now feel more confident in suggesting appropriate follow-up actions based on cfDNA results?
- Can you identify instances where your interpretation of cfDNA results has contributed to clinical decision-making?
- Have the analytical and interpretative skills developed in this activity been transferable to the interpretation of other complex molecular diagnostic tests?
- How will your experience in interpreting cfDNA assays prepare you for the increasing use of liquid biopsies in clinical practice?
- Will your ability to link cfDNA results to potential therapeutic interventions be a valuable asset in personalised medicine strategies?
- How might this experience contribute to your professional development and potential involvement in the implementation or validation of new cfDNA-based assays?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Practice in accordance with legislation regarding use of human tissue. |
| # 3 |
Outcome
Appraise the application of novel and evolving therapies in the treatment of haematological conditions. |